Literature DB >> 24616389

Which type of conduit to choose for right ventricular outflow tract reconstruction in patients below 1 year of age?†.

Keti Vitanova1, Julie Cleuziou2, Jürgen Hörer1, Jelena Kasnar-Samprec1, Manfred Vogt3, Christian Schreiber1, Rüdiger Lange1.   

Abstract

OBJECTIVES: Reconstruction of the right ventricular outflow tract (RVOT) with a conduit in patients below 1 year of age remains a matter of concern due to limited availability and durability of conduits. We sought to analyse the freedom from conduit exchange in this subgroup of patients by comparing different conduits.
METHODS: Data of 145 consecutive patients below 1 year of age, requiring a conduit for RVOT reconstruction between 1994 and 2011 were reviewed. The endpoints of the study were defined as: 'conduit exchange for any reason', 'at least moderate conduit stenosis' and 'at least moderate insufficiency'.
RESULTS: Homografts, bovine jugular vein conduits (Contegra) and porcine-valved Dacron conduits (Hancock) were implanted in 62 (43%), 35 (24%) and 48 (33%) patients, respectively. The mean conduit diameter was 12.9 ± 1.3 mm. A conduit exchange was necessary in 72 patients (55%) at a median time of 5.9 years [1.1-10.8]. The rate of freedom from conduit exchange at 5 years was 69.4 ± 6.6, 59.4 ± 8.7 and 53.8 ± 7.4%, respectively (P = 0.4). The rate of freedom from at least moderate stenosis was 85.4 ± 5.6, 75.1 ± 9.1 69.1 ± 7.9% at 5 years and 59.2 ± 11.1, 35.8 ± 12.0, 49.7 ± 10.1% at 10 years, for homografts, Contegra and Hancock conduits, respectively. The rate of freedom from at least moderate conduit insufficiency was 91.7 ± 4, 74.6 ± 9.1, 86.9 ± 7.4% at 5 years and 64.8 ± 14.1, 44.2 ± 13.7, 52.1 ± 14.2% at 10 years, for homografts, Contegra and Hancock conduits, respectively. Patients with a Contegra conduit developed moderate conduit stenosis or insufficiency faster than patients with a homograft (P = 0.01). Age below 1 month and heterotopic implantation of the conduit emerged as risk factors for conduit exchange in the univariate analysis (P = 0.05, P = 0.02, respectively). There was no significant influence of the conduit type, conduit size, z-score or the body surface area. In the multivariate analysis, heterotopic implantation emerged as the only risk factor for conduit exchange (P = 0.02, hazard ratio = 1.6, 95% confidence interval = 1.0-2.7).
CONCLUSIONS: Homografts, bovine jugular vein conduits and porcine-valved Dacron conduits exhibit equal durability after implantation in patients below 1 year of age independent of their size. Nonetheless, moderate conduit stenosis or insufficiency develops earlier in patients with a Contegra conduit. Conduit placement in the neonatal period and implantation in a heterotopic position shortens the durability.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Congenital heart disease; Neonate; Right ventricular outflow tract

Mesh:

Year:  2014        PMID: 24616389     DOI: 10.1093/ejcts/ezu080

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  12 in total

1.  Mid- to long-term outcomes of bovine jugular vein conduit implantation in Chinese children.

Authors:  Hui-Feng Zhang; Gang Chen; Ming Ye; Xian-Gang Yan; Qi-Lin Tao; Bing Jia
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

2.  Is there any progress in the search for the ideal conduit for reconstruction of the right ventricular outflow tract in young children?

Authors:  Julie Cleuziou
Journal:  Transl Pediatr       Date:  2018-07

Review 3.  In Search of the Ideal Valve: Optimizing Genetic Modifications to Prevent Bioprosthetic Degeneration.

Authors:  Benjamin Smood; Hidetaka Hara; David C Cleveland; David K C Cooper
Journal:  Ann Thorac Surg       Date:  2019-03-02       Impact factor: 4.330

4.  Mid-term outcomes of Contegra implantation for the reconstruction of the right ventricular outflow tract to proximal branch pulmonary arteries: Japan multicentre study.

Authors:  Takaya Hoashi; Hajime Ichikawa; Keiichi Hirose; Naohiro Horio; Takahisa Sakurai; Hironori Matsuhisa; Yoshihiro Ohsima; Hajime Sakurai; Shingo Kasahara; Kisaburo Sakamoto
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-07-26

Review 5.  The Real Need for Regenerative Medicine in the Future of Congenital Heart Disease Treatment.

Authors:  Yuichi Matsuzaki; Matthew G Wiet; Brian A Boe; Toshiharu Shinoka
Journal:  Biomedicines       Date:  2021-04-27

6.  Injectable tissue engineered pulmonary heart valve implantation into the pig model: A feasibility study.

Authors:  Franziska Schlegel; Aida Salameh; Katja Oelmann; Michelle Halling; Stefan Dhein; Friedrich W Mohr; Pascal M Dohmen
Journal:  Med Sci Monit Basic Res       Date:  2015-06-24

7.  Wharton's Jelly-Mesenchymal Stem Cell-Engineered Conduit for Pulmonary Artery Reconstruction in Growing Piglets.

Authors:  Filippo Rapetto; Dominga Iacobazzi; Srinivas A Narayan; Katie Skeffington; Tasneem Salih; Shahd Mostafa; Valeria V Alvino; Adrian Upex; Paolo Madeddu; Mohamed T Ghorbel; Massimo Caputo
Journal:  JACC Basic Transl Sci       Date:  2022-02-23

8.  Hand-Made Polytetrafluoroethylene Tricuspid-Valved Conduit for Surgical Reconstruction of the Right Ventricular Outflow Tract in a Child With Truncus Arteriosus.

Authors:  Vishal V Bhende; Tanishq S Sharma; Hardil P Majmudar; Krishnan Ganapathy Subramaniam; Deepakkumar V Mehta; Amit Kumar; Purvi R Patel; Gurpreet Panesar; Kunal Soni; Kartik B Dhami; Nirja Patel; Sohilkhan R Pathan
Journal:  Cureus       Date:  2022-07-20

9.  Homograft durability after correction of pulmonary atresia and ventricular septal defect with or without systemic pulmonary collateral arteries.

Authors:  Pieter C van de Woestijne; Jamie L R Romeo; Ingrid van Beynum; Maarten Witsenburg; M Mostafa Mokhles; Ad J J C Bogers
Journal:  JTCVS Open       Date:  2021-09-24

10.  Impact of valve fenestrations and structural changes in homografts on the long-term outcome in the recipient.

Authors:  Ida Axelsson; Torsten Malm; Johan Nilsson
Journal:  Cell Tissue Bank       Date:  2021-02-12       Impact factor: 1.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.